See Point-Counterpoint articles on pages 1474 and 1478.
Bhushan and Apte1 highlight the beneficial effects of bile acids (BAs), such that increasing BA levels stimulate regeneration and recovery after partial hepatectomy (PH) or drug-induced acute liver injury. Although we agree with the protective role of BAs in liver regeneration, increasing evidence points to the fact that the composition of the BA pool is crucial for downstream signaling.
Hydrophobic BAs induce cytotoxicity while hydrophilic BAs alleviate liver injury, and the ratio of BAs in the pool determines the hydrophobic index. Deletion of small heterodimer partner2 and a lithocholic acid–enriched diet3 both can increase the hydrophobic BA pool, causing bile infarcts, bile duct obstruction, and liver injury. Moreover, altered BA composition after PH has been noted with a particular increase in cholic acid and a reduction in chenodeoxycholic acid, resulting in a more hydrophilic BA pool during regeneration. Mechanistically, the membrane Takeda G-protein–coupled receptor activation modulates BA composition to become more hydrophilic, and thus protects against cytotoxic BA accumulation.4
However, if the BA composition became more hydrophobic, it correlates with increased liver injury after PH in human beings and mice.4 Mouse models with hydrophobic BA composition, including Cyp2c70 knockout and Cyp2a12/Cyp2c70 double-knockout mice, show inflammation and injury in the liver despite having a reduced overall BA concentration.5 In addition, increasing evidence has shown that changes in BA composition can modulate immune responses in the liver and contribute to the pathogenesis of inflammatory diseases.6
BAs also activate cell death and survival pathways, and the balance between these signals determines the beneficial or toxic effects of specific BAs in the liver. For example, hydrophilic ursodeoxycholic acid induces hepatocyte apoptosis to clear them from inherent BA toxicity, whereas taurine conjugate of a slightly hydrophobic BA, chenodeoxycholic acid, facilitates survival pathways and hepatocyte proliferation.7
Apart from receptor-based cellular signaling, more recent data have uncovered the role of the gut microbiota–BA axis in several liver diseases. In fact, gut microbiota can facilitate the production of novel phenylalanine- and tyrosine-conjugated cholic acids that are enriched in disease conditions in human beings.8 Furthermore, in patients with intrahepatic cholangiocarcinoma, gut microbiota correlate with BA levels and composition along with inflammatory cytokines.9
Therefore, appropriate regulation of BA composition, hydrophobic index, and overall concentration will influence if the outcome in the liver will be harmful or beneficial.
“Light. Darkness. A balance.” -The Last Jedi
Footnotes
Conflicts of interest The authors disclose no conflicts.
Funding Supported by grants R01 DK113080 from the National Institute of Diabetes and Digestive and Kidney Diseases, Research Scholar Grant 132640 from the American Cancer Society, and planning grant 6741 from the Cancer Center at Illinois (S.A.).
References
- 1.Bhushan Bharat, Apte Udayan. The Benevolent Bile: Bile Acids as Stimulants of Liver Regeneration. Cell Mol Gastroenterol Hepatol. 2022;13:1478–1480. doi: 10.1016/j.jcmgh.2022.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Park Y.J., Qatanani M., Chua S.S., LaRey J.L., Johnson S.A., Watanabe M., Moore D.D., Lee Y.K. Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasis. Hepatology. 2008;47:1578–1586. doi: 10.1002/hep.22196. [DOI] [PubMed] [Google Scholar]
- 3.Fickert P., Fuchsbichler A., Marschall H.U., Wagner M., Zollner G., Krause R., Zatloukal K., Jaeschke H., Denk H., Trauner M. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol. 2006;168:410–422. doi: 10.2353/ajpath.2006.050404. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bidault-Jourdainne V., Merlen G., Glenisson M., Doignon I., Garcin I., Pean N., Boisgard R., Ursic-Bedoya J., Serino M., Ullmer C., Humbert L., Abdelrafee A., Golse N., Vibert E., Duclos-Vallee J.C., Rainteau D., Tordjmann T. TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload. JHEP Rep. 2021;3 doi: 10.1016/j.jhepr.2020.100214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Honda A., Miyazaki T., Iwamoto J., Hirayama T., Morishita Y., Monma T., Ueda H., Mizuno S., Sugiyama F., Takahashi S., Ikegami T. Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition. J Lipid Res. 2020;61:54–69. doi: 10.1194/jlr.RA119000395. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Evangelakos I., Heeren J., Verkade E., Kuipers F. Role of bile acids in inflammatory liver diseases. Semin Immunopathol. 2021;43:577–590. doi: 10.1007/s00281-021-00869-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Guicciardi M.E., Gores G.J. Bile acid-mediated hepatocyte apoptosis and cholestatic liver disease. Dig Liver Dis. 2002;34:387–392. doi: 10.1016/s1590-8658(02)80033-0. [DOI] [PubMed] [Google Scholar]
- 8.Quinn R.A., Melnik A.V., Vrbanac A., Fu T., Patras K.A., Christy M.P., Bodai Z., Belda-Ferre P., Tripathi A., Chung L.K., Downes M., Welch R.D., Quinn M., Humphrey G., Panitchpakdi M., Weldon K.C., Aksenov A., da Silva R., Avila-Pacheco J., Clish C., Bae S., Mallick H., Franzosa E.A., Lloyd-Price J., Bussell R., Thron T., Nelson A.T., Wang M., Leszczynski E., Vargas F., Gauglitz J.M., Meehan M.J., Gentry E., Arthur T.D., Komor A.C., Poulsen O., Boland B.S., Chang J.T., Sandborn W.J., Lim M., Garg N., Lumeng J.C., Xavier R.J., Kazmierczak B.I., Jain R., Egan M., Rhee K.E., Ferguson D., Raffatellu M., Vlamakis H., Haddad G.G., Siegel D., Huttenhower C., Mazmanian S.K., Evans R.M., Nizet V., Knight R., Dorrestein P.C. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020;579:123–129. doi: 10.1038/s41586-020-2047-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Jia X., Lu S., Zeng Z., Liu Q., Dong Z., Chen Y., Zhu Z., Hong Z., Zhang T., Du G., Xiang J., Wu D., Bai W., Yang B., Li Y., Huang J., Li H., Safadi R., Lu Y. Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma. Hepatology. 2020;71:893–906. doi: 10.1002/hep.30852. [DOI] [PubMed] [Google Scholar]